Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22963909 | 0.98 | MEN1 (0.61) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL19040656 | 0.96 | TSHR (0.54) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL9746008 | 0.90 | LMNA (0.54) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL976681 | 0.90 | MEN1 (0.73) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL9233920 | 0.89 | LMNA (0.48) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL977876 | 0.88 | MEN1 (0.70) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL23640550 | 0.88 | MEN1 (0.64) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL973842 | 0.86 | MEN1 (0.68) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL102719 | 0.85 | LMNA (0.44) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL25757738 | 0.83 | TSHR (0.52) | TSHRMEN1KMT2ATHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369705-A1 | COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS | MERCK PATENT GMBH (DE) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369705-A1 | COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS | ATR, TOP2A, TOP1 | TSHR 1662/4885MEN1 2468/4885KMT2A 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.